



CIN No. : L24230TG1995PLC020093

CONCORD DRUGS LIMITED

Regd. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R. Dist. - 501 511. (T.S) INDIA.

Admin Office : 3-11-451, L B Nagar, Hyderabad - 500074

E-mail : concorddrugsltd@gmail.com

Ph.No : +91 9052779505

Website : www.concorddrugs.in

To,

Date: 14.11.2022

BSE Limited
P.J. Towers, Dalal Street
Mumbai- 400001

Dear Sir/ Madam,

Sub: Outcome of Board Meeting held on 14.11.2022

Ref: Our Company's letter dated 02.11.2022

Unit: Concord Drugs Limited

With reference to the subject cited, this is to inform the exchange that the Board of Directors of **Concord Drugs Limited** at its meeting held on Monday, the 14th day of November, 2022 at the registered office of the company at 4:30 p.m., approved the following items of business:

1. Un-audited Financial Results for the Quarter and Half year ended 30th September, 2022. (Enclosed as Annexure).
2. Limited Review Report for the Quarter ended 30th September, 2022. (Enclosed as Annexure).

The meeting concluded at 5.15 p.m.

This is for the information and records of the Exchanges, please.

Thanking you.

Yours sincerely,
For Concord Drugs Limited

S. Nagi Reddy

S. Nagi Reddy
Chairman & Managing Director
(DIN- 01764665)
Encl. as above





CIN No. : L24230TG1995PLC020093

CONCORD DRUGS LIMITED

Regd. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R. Dist. - 501 511. (T.S) INDIA.

Admin Office : 3-11-451, L B Nagar, Hyderabad - 500074

E-mail : concorddrugsltd@gmail.com

Ph.No : +91 9052779505

Website : www.concorddrugs.in

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 30th september 2022

(Rs. in Lakhs)

Particulars	Quarterly ended			half year ended		Year ended
	30-Sep-22	30-Jun-22	30-Sep-21	30-Sep-22	30-Sep-21	31-Mar-22
	(UnAudited)	(unAudited)	UnAudited	(UnAudited)	(UnAudited)	(Audited)
I Revenue from Operations						
a. Net sales from Operations	1,371.56	1,253.15	983.08	2,624.71	3,005.02	5,895.65
b. Other Operating Income	0.09	0.60	2.80	0.70	4.95	10.08
II Other Income						
III Total Revenue (I+II)	1,371.65	1,253.75	985.88	2,625.40	3,009.97	5,905.73
IV Expenses						
a. Cost of Material Consumed	1,105.85	869.11	743.09	1,974.96	2,309.58	4,441.15
b. Changes in Inventories of finished goods, work-in-progress and stock-in-trade	-31.31	107.61	72.21	76.30	53.73	231.06
c. Employees Benefit Expenses	115.06	116.17	103.82	231.23	208.70	489.10
d. Finance Costs	42.05	33.83	30.55	75.88	126.31	168.07
e. Depreciation and Amortisation expense	52.69	38.88	56.67	91.56	109.84	176.45
f. Other expenses	63.43	62.83	44.53	126.26	149.82	637.21
Total Expenses	1,347.76	1,228.43	906.45	2,576.19	2,850.52	5,680.92
Profit/ (Loss) before Exceptional item and tax (III-IV)	23.89	25.33	79.43	49.22	159.45	224.81
V Exceptional Items						
VI Profit/ (Loss) before tax (V-VI)	23.89	25.33	79.43	49.22	159.45	224.81
VII Tax Expense:						
a. Current tax	5.74	6.59	33.63	12.33	44.89	65.37
b. Deferred tax charge/credit	9.074	6.63	27.74	15.71	52.42	67.12
VIII Profit/ (Loss) for the period (VII-VIII)	18.146	18.74	45.80	36.89	114.56	159.44
X Other Comprehensive Income						
Items that will not be reclassified to profit or loss	-	-	-	-	-	-
Total Comprehensive Income for the period (comprising profit and other comprehensive income for the period) (IX+X)	18.15	18.74	45.80	36.89	114.56	159.44
XI Paid-up equity share capital (Face value of the share- Rs. 10 each)	874.38	874.38	874.38	874.38	874.38	874.38
Other Equity	1,998.57	1,980.43	1,916.81		1,916.81	1,961.680
XII Earnings per share (of Rs. 10 each)						
XIII a. Basic (in Rs)	0.21	0.21	0.52	0.42	1.31	1.82
b. Diluted (in Rs)	0.21	0.21	0.52	0.42	1.31	1.82

Notes:

- The financial results of the company have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under section 133 of the Companies Act, 2013, read with the relevant rules issued there under.
- The above standalone financial results as reviewed by the audit committee have been approved by Board of Directors at its meeting held on 14th November, 2022
- Figures of the corresponding previous periods are regrouped and reclassified wherever considered necessary to correspond with current periods' presentation.
- The results are also available on the website of the Company www.concorddrugs.in

By Order of the Board
For Concord Drugs LimitedS. Nagi Reddy
Managing Director
DIN: 01764665Place: Hyderabad
Date: November 14, 2022



CIN No. : L24230TG1995PLC020093

CONCORD DRUGS LIMITED

Regd. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R. Dist. - 501 511. (T.S) INDIA.


Admin Office : 3-11-451, L B Nagar, Hyderabad - 500074

E-mail : concorddrugsLtd@gmail.com

Ph.No : +91 9052779505

Website : www.concorddrugs.in

Concord Drugs Limited Survey No 249 , Brahmanapally Village Hayathnagar Mandal RR District, Pin - 501511, Telangana		
Un Audited Balance sheet as at 30th September , 2022		
Rs in Lakh		
Particulars	As At Sep 30, 2022	As At March 31, 2022
ASSETS		
Non-current assets		
(a) Property, plant and equipment	1,263.59	1,332.92
(b) Capital Work-in Progress	64.90	55.39
(b) Investment property	63.95	63.95
Financial assets		
(a) Loans & Advances	3.73	3.19
Other Non current assets	-	-
Total Non - Current Assets	1,396.17	1,455.45
Current Assets		
Inventories	1,672.69	1,748.99
Financial assets		
(a) Investments		
(b) Trade receivables	2,115.16	2,285.85
(c) Cash and cash equivalents	30.92	4.44
(d) Bank balances other than (c) above	2.10	2.10
(e) Other Current Financial Assets	10.07	10.07
Other current assets	162.25	137.61
Total Current assets	3,993.20	4,189.07
Total Assets	5,389.365	5,644.51
EQUITY AND LIABILITIES		
Equity		
Equity share capital	874.38	874.38
Other equity	1,998.57	1,961.68
Total Equity	2,872.95	2,836.06
Non-current liabilities		
Financial Liabilities		
(a) Borrowings	223.00	248.26
(b) Trade payables		
Deferred tax liabilities, net	62.54	65.92
Provisions	208.38	208.38
Government Grants	-	-
Total Non-current liabilities	493.92	522.56
Current liabilities		
Financial liabilities		
(a) Borrowings	1,530.88	1,395.17
(b) Trade payables	265.42	717.88
(c) Other Current financial liabilities	-	-
Current tax liabilities, net	82.84	67.13
Other current liabilities	143.36	105.72
Total Current liabilities	2,022.50	2,285.90
Total liabilities	2,516.42	2,808.45
Total Equity and liabilities	5,389.370	5,644.51

By Order of the Board
For Concord Drugs Limited
S. Nagi Reddy

Managing Director

DIN: 01764665

Place: Hyderabad

Date: November 14, 2022





CIN No. : L24230TG1995PLC020093

CONCORD DRUGS LIMITED

Regd. Office & Factory : Survey No. 249, Brahmanapally Village, Hayathnagar Mandal, R.R. Dist. - 501 511. (T.S) INDIA.

Admin Office : 3-11-451, L B Nagar, Hyderabad - 500074

E-mail : concorddrugsLtd@gmail.com

Ph.No : +91 9052779505

Website : www.concorddrugs.in

Concord Drugs Limited Survey No 249 , Brahmanapally Village Hayathnagar Manadal RR District, Pin - 501511, Telangana			
Un Audited Statement of Cash flow at at 30th Sep, 2022		Rs in Lakhs	
Particulars	As at Sep 30, 2022	As at March 31, 2022	
A. CASH FLOW FROM OPERATING ACTIVITIES			
Profit Before Tax		49.217	224.81
<i>Adjustments for:</i>			
<i>Profit on sale of ASSETS</i>			
Depreciation and amortisation expense	91.56	176.45	
Finance costs	72.78	141.33	
Interest income	(0.60)	-1.23	
Provision for Gratutly		163.74	316.55
Operating profit before working capital changes		212.96	541.36
<i>Changes in working capital:</i> (Refer Note 40)			
<i>Adjustments for (increase) / decrease in operating assets:</i>			
Financial Assets			
Trade receivables	170.69	-213.04	
Loans and Advances	(0.54)	-0.55	
Other Non Current assets		-	
Inventories	76.30	-561.81	
Other Current assets	(24.65)	194.87	
Other bank balances		-	
Other Current financial Assets		-5.66	
<i>Adjustments for increase / (decrease) in operating liabilities:</i>			
Trade payables	(452.46)	403.11	
Borrowings		-	
Other current financial liabilities		-	
Other current liabilities	37.64	-233.81	
Current tax liabilities, net	15.71	20.06	
Provisions		-	
Deferred tax on amalgamation		-	
Cash generated from operations		35.66	144.54
Net income tax paid		(15.71)	(67.12)
Net cash flow from operating activities (A)		19.949	77.42
B. CASH FLOW FROM INVESTING ACTIVITIES			
Capital expenditure on fixed assets, including capital advances (Refer Note (iii) below)	-31.75	(245.61)	
Proceeds from maturity of fixed deposits		-	
- Others	0.60	1.23	
Net cash (used in) / flow from investing activities (B)		(31.143)	(244.39)
C. CASH FLOW FROM FINANCING ACTIVITIES			
Proceeds from issue of equity shares		-	
Finance costs	-72.78	(141.33)	
Repayment of Borrowings	-25.26	(126.85)	
Repayment of short term Borrowings	135.71	472.96	
Govt Grants		(36.92)	
Other equity Adjustment		-	
Net cash flow (used in) financing activities (C)		37.668	167.86
Net (decrease) in Cash and cash equivalents (A+B+C)		26.47	0.89
Cash and cash equivalents at the beginning of the year		4.442	3.55
Effect of exchange differences on translation of foreign currency Cash and cash equivalents		-	-
Cash and cash equivalents at the end of the year (Refer Note (i) below)		30.92	4.44
* Comprises:			
Balances with Banks		-	0.50
Others		30.92	3.94
		30.92	4.44

Place: Hyderabad

Date: November 14, 2022

By Order of the Board
For Concord Drugs LimitedS. Nagi Reddy
Managing Director
DIN: 01764665



PUNDARIKASHYAM AND ASSOCIATES

CHARTERED ACCOUNTANTS

D.No. 3-6-666, 3rd Floor, Barwale Chambers, Street No.11, Himayat Nagar,
Hyderabad - 500 029, Cell : 9440464339, Ph : 040 - 40072693,
E-mail: info@pkas.in / infoong@pkas.in / info.vizag@pkas.in

GSTIN : 36AAJFP6218J1ZY

- Branches : 1. Door No. 76-14-243/1A, Vasavi Kalyana Mandapam Road, Sivalayam Centre, Bhavani Puram, Vijayawada - 12.
2. 7-310, Shop No. 204, Padma Towers, South Bypass Road, Ongole, 523001.
3. Flat No. 202, 2nd Floor, Vijaya Ganapathi Nilayam, Ayyappa Nagar, Murali Nagar, Near Masjid Junction, Visakhapatnam, Andhra Pradesh - 530007.

Independent Auditor's Review Report on Standalone Unaudited Quarterly and Year to Date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)


To the Board of Directors of Concord Drugs Limited,

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Concord Drugs Limited ('the company') for the quarter ended 30 September 2022, and the year to date results for the period 1 April 2022 to 30 September 2022, being submitted by the Company pursuant to the requirements of the regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time. Attention is drawn to the fact that the cash flow figures for the corresponding six month period ended 30 September 2022 have been approved by the Company's Board of Directors, but have not been subjected to audit or review.
2. The statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the act'), SEBI circular CIR/CFD/FAC/62/2016, dated 5 July 2016, (hereinafter referred to as 'the SEBI Circular'), and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE)2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under Section 133 of the Act, the SEBI Circular, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Pundarikashyam and Associates
Chartered Accountants
FRN: 011330S.

B. Surya Prakasa Rao


B.Surya Prakasa Rao
(Partner)

MNo: 205125

UDINNo: 22205125 BDB WCK 8571.

Place: Hyderabad

Date: 14-11-2022.